Product Licensing

Licensing agreement signed for drug delivery technology for drug eluting stents

Published in Gene Therapy Weekly, August 18th, 2005

Kenneth Carpenter, president and CEO of MediVas LLC, and Dr. Marc Lussier, chief executive officer of Estracure, Inc., (DUVT, DUVT.ETR) announced the signing of an agreement for the exclusive use of the MediVas PEA drug delivery technology in conjunction with Estracure's core technology to develop a 17-(beta)-Estradiol drug-eluting stent (DES) to treat patients suffering from coronary heart diseases.

The development of drug eluting stents has grown rapidly since DES became the standard of care for treating coronary blockages in the U.S. and in Europe. Latest clinical research findings indicate that DES reduce the need for repeat percutaneous transluminal coronary...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry